Mirum Pharmaceuticals (NASDAQ:MIRM) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a report issued on Friday, Benzinga reports. They currently have a $66.00 price objective on the stock.

A number of other research analysts have also commented on MIRM. Baird R W raised Mirum Pharmaceuticals to a strong-buy rating in a report on Monday, June 17th. JMP Securities increased their price target on Mirum Pharmaceuticals from $66.00 to $68.00 and gave the company a market outperform rating in a report on Tuesday, June 18th. JPMorgan Chase & Co. boosted their price objective on shares of Mirum Pharmaceuticals from $31.00 to $39.00 and gave the stock an overweight rating in a research note on Tuesday, June 18th. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $34.00 to $39.00 and gave the company an outperform rating in a research note on Monday, June 17th. Finally, Morgan Stanley boosted their target price on shares of Mirum Pharmaceuticals from $53.00 to $57.00 and gave the stock an overweight rating in a research report on Tuesday, June 18th. Ten research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of Buy and a consensus price target of $53.64.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $42.05 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.47 and a current ratio of 3.68. The firm has a market cap of $1.98 billion, a PE ratio of -11.33 and a beta of 1.15. Mirum Pharmaceuticals has a twelve month low of $23.14 and a twelve month high of $44.70. The firm’s 50 day moving average price is $32.01 and its 200 day moving average price is $28.39.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.14). The business had revenue of $69.22 million for the quarter, compared to the consensus estimate of $69.71 million. Mirum Pharmaceuticals had a negative net margin of 69.67% and a negative return on equity of 56.46%. As a group, research analysts expect that Mirum Pharmaceuticals will post -1.66 EPS for the current fiscal year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, insider Pamela Vig sold 30,559 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $34.00, for a total transaction of $1,039,006.00. Following the sale, the insider now owns 27,406 shares of the company’s stock, valued at approximately $931,804. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Pamela Vig sold 30,559 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $34.00, for a total value of $1,039,006.00. Following the sale, the insider now owns 27,406 shares of the company’s stock, valued at $931,804. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Saira Ramasastry sold 5,000 shares of the stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $25.68, for a total transaction of $128,400.00. The disclosure for this sale can be found here. Insiders sold a total of 35,934 shares of company stock valued at $1,180,156 in the last quarter. Corporate insiders own 22.87% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. lifted its holdings in shares of Mirum Pharmaceuticals by 18.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 266,681 shares of the company’s stock valued at $7,872,000 after acquiring an additional 42,110 shares during the period. California State Teachers Retirement System increased its position in shares of Mirum Pharmaceuticals by 672.9% during the 4th quarter. California State Teachers Retirement System now owns 211,111 shares of the company’s stock worth $6,232,000 after purchasing an additional 183,798 shares in the last quarter. CenterBook Partners LP lifted its holdings in Mirum Pharmaceuticals by 242.4% during the 4th quarter. CenterBook Partners LP now owns 51,837 shares of the company’s stock valued at $1,530,000 after purchasing an additional 36,699 shares during the last quarter. TD Asset Management Inc acquired a new position in Mirum Pharmaceuticals in the fourth quarter valued at about $1,387,000. Finally, Boone Capital Management LLC grew its stake in Mirum Pharmaceuticals by 25.7% during the fourth quarter. Boone Capital Management LLC now owns 490,139 shares of the company’s stock worth $14,469,000 after buying an additional 100,348 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.